ArticleBMC cardiovascular disorders2025
Analysis of the relative risk factors for H-type hypertension and its correlation with the MTHFR C677T genotype in a health checkup population in Urumqi, China-a cross-sectional study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and comparative performance of machine learning models for stroke risk prediction in hypertensive patients: A systematic review and meta-analysis.International journal of cardiology. Cardiovascular risk and prevention · 2026Review
- Muscle Ultrasound Parameters and Cognitive Function in H‑type Hypertension: A Cross-Sectional Study.Clinical interventions in aging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThis cross-sectional survey investigated the incidence of H-type hypertension and associated risk factors in a health checkup population in Urumqi, China. We aimed to identify potential intervention targets by screening patients with H-type hypertension and high-risk populations, filling the gap in the risk assessment of H-type hypertension in high-altitude areas.
methodsFrom January 2023 to January 2024, we conducted a cross-sectional study on 1,772 individuals who underwent methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism evaluations. We included a questionnaire survey and collected physical measurements and blood samples. The relative risk factors related to H-type hypertension, as well as their correlation with the MTHFR C677T genotype, were subsequently analyzed.
resultsH-type hypertension was present in 68.96% of hypertension cases and 17.55% of the population in Urumqi who underwent health checkups. The methylenetetrahydrofolate reductase (MTHFR) C677T distributions of the CC, CT, and TT genotypes were 11.90%, 39.87%, and 48.23%, respectively. Moreover, multivariate logistic regression identified the MTHFR C677T TT genotype, age, triglyceride-glucose index (TyG), and carotid plaques as risk factors related to H-type hypertension, with odds ratios (ORs) of 3.044 (p < 0.001), 1.041 (p = 0.001), 1.385 (p = 0.003), and 1.748 (p < 0.001), respectively. In addition, high-density lipoprotein (HDL) cholesterol was identified as a protective factor (OR = 0.447, p = 0.002). Through regression analysis, a nomogram model was constructed to predict the incidence of H-type hypertension. This model showed a good fit, and the area under the receiver operating characteristic (ROC) curve (AUC) was 0.760. Its predicted H-type hypertension incidence was closely related to the actual incidence.
conclusionsAccording to our findings, the MTHFR C677T TT genotype in Urumqi, China, serves as a risk locus related to H-type hypertension. Moreover, age, TyG, and carotid plaques are risk factors for H-type hypertension, whereas HDL is a protective factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.